Showing 1 to 1 of 1 results
cnbc.com
🌐 85% Global Worthiness
J&J's Lung Cancer Drug Extends Life by at Least a Year
Johnson & Johnson announced Tuesday that its two-drug lung cancer regimen, Rybrevant and Lazcluze, extends life expectancy by at least a year compared to AstraZeneca's Tagrisso, based on a pivotal trial, though the regimen has more side effects.
J&J's Lung Cancer Drug Extends Life by at Least a Year
Johnson & Johnson announced Tuesday that its two-drug lung cancer regimen, Rybrevant and Lazcluze, extends life expectancy by at least a year compared to AstraZeneca's Tagrisso, based on a pivotal trial, though the regimen has more side effects.
Progress
60% Bias Score
Good Health and Well-being
Showing 1 to 1 of 1 results